Search results
15 wrz 2022 · Complete thrombus resolution was achieved in 62.3% (n=99) at a median of 103 days (interquartile range, 32–392 days). 17 Recurrence of thrombus or an increase in LV thrombus area was observed in 14.5% (n=23), a finding associated with poor adherence, prothrombotic conditions, and increased mortality. 17.
- View EPUB
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Linda S. Williams
Sleep SMART (Sleep for Stroke Management and Recovery...
- PDF/Epub
PK u!3Yoa«, mimetypeapplication/epub+zipPK u!3Y...
- Trial
Background—The Randomized Evaluation of Long-term...
- Results From the GEIST
Left ventricular (LV) thrombus formation is a well‐known...
- Intraventricular Thrombus Formation and Embolism in Takotsubo Syndrome
Objective: Takotsubo syndrome (TTS) is characterized by...
- Stroke
National Center. 7272 Greenville Ave.Dallas, TX 75231....
- Peripartum Cardiomyopathy
Peripartum cardiomyopathy is a potentially life-threatening...
- View EPUB
Left ventricular (LV) thrombus is a feared complication of LV dysfunction associated with high rates of systemic embolism, morbidity, and mortality. Traditionally, LV thrombus has been associated with acute myocardial infarction (MI).
27 cze 2023 · Management Options for LVT Persistence. In large observational studies, the rate of thrombus resolution at 6 months ranged from more than 80% to as low as 30%. 26,40 In the setting of persistent LVT, most studies continued anticoagulation or switched to a different anticoagulant (Table 2).
17 kwi 2023 · Exclusion criteria included the presence of thrombus in another cardiac chamber (left atrium, right atrium, or right ventricle), incomplete TTE, participant survival time <6 months, or lost to follow‐up.
LVT should be considered a marker of increased long-term thrombotic risk that may persist even after thrombus resolution. Ongoing clinical trials are expected to elucidate the best management strategies for patients with LVT.
Management of LV thrombus (LVT) is challenging and crucial to prevent the potential development of thromboembolic complications such as stroke. Anticoagulation with warfarin is recommended for the prevention of thromboembolic events, but novel oral anticoagulants (NOAC) have been used in clinical practice without supporting evidence.
23 wrz 2022 · If OAC is initiated, a treatment duration might be 1–3 months, depending on bleeding risk. On the basis of reasonable data and evidence, post-MI patients with LV thrombus should be treated with OAC, typically for a duration of 3 months.
